D. Boral Capital reaffirmed their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) in a report published on Tuesday,Benzinga reports. The firm currently has a $32.00 price ...

Highlights,Maze Therapeutics is a clinical-stage biopharmaceutical company focused on precision medicines for renal, ...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NewAmsterdam Pharma Company (NAMS – Research ...

Acadia Pharmaceuticals ACAD reported fourth-quarter 2024 earnings of 17 cents per share, missing the Zacks Consensus Estimate ...

Leerink Partnrs upgraded shares of Maze Therapeutics (NASDAQ:MAZE – Free Report) to a strong-buy rating in a report released ...